On December 14, Gelonghui (300683.SZ) announced that according to the “Notice on Issuance” (Health Insurance<国家基本医疗保险、工伤保险和生育保险药品目录 (2023 年) > Development [2023] No. 30) issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, the company's injectable tedizolamide phosphate was included for the first time in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2023)” (hereinafter referred to as the “2023 National Health Insurance Catalogue”).

Tedizolamide phosphate is an antibiotic that is a precursor to oxazolidone. It is rapidly converted by phosphatase into the active ingredient tedizolamide in the body and exerts an antibacterial effect by inhibiting protein synthesis by binding to the 50S subunit of bacterial ribosomes. Injectable tedizolamide phosphate is suitable for the treatment of acute bacterial skin and skin soft tissue infections (ABSSSI) caused by sensitive isolates of the following gram-positive bacteria: Staphylococcus aureus (including isolates of methicillin-resistant Staphylococcus aureus [MRSA] and methicillin-sensitive Staphylococcus aureus [MSSA]), streptococcus pyogenes, streptococci aginosa, streptococci pharyngitis (including streptococci pharyngitis, middle streptococci, and streptococci) and enterococci.